PMID- 16236930
OWN - NLM
STAT- MEDLINE
DCOM- 20051121
LR  - 20181201
IS  - 0012-3692 (Print)
IS  - 0012-3692 (Linking)
VI  - 128
IP  - 4
DP  - 2005 Oct
TI  - Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension.
PG  - 2599-603
AB  - BACKGROUND: Bosentan, an oral endothelin (ET)-A/ET-B receptor antagonist, is 
      effective in the treatment of pulmonary arterial hypertension. OBJECTIVE: To 
      investigate the safety and efficacy of bosentan therapy in patients with 
      inoperable chronic thromboembolic pulmonary hypertension (CTEPH). DESIGN: Case 
      series. SETTING: Pulmonary Hypertension Unit of the Medical University of Vienna, 
      Austria. PATIENTS: Sixteen patients (9 women and 7 men; mean age +/- SD, 70 +/- 
      13 years). INTERVENTION: Off-label bosentan treatment over 6 months. 
      MEASUREMENTS: Changes from baseline in liver enzymes, New York Heart Association 
      (NYHA) functional class, 6-min walking distance (6-MWD), and serum amino-terminal 
      pro-brain natriuretic peptide (proBNP). RESULTS: After 6 months, NYHA functional 
      class improved by one class in 11 patients. Mean 6-MWDs increased from 299 +/- 
      131 m at baseline to 391 +/- 110 m at 6 months (p = 0.01). In parallel, proBNP 
      decreased from 3,365 +/- 2,923 to 1,755 +/- 1,812 pg/mL (p = 0.01). Neither 
      aspartate aminotransferase (25 +/- 2 U/L vs 25 +/- 2 U/L, p = 0.25) nor alanine 
      aminotransferase (23 +/- 12 U/L vs 24 +/- 9 U/L, p = 0.57) changed significantly. 
      Limitations of the study were uncontrolled design and small sample size. 
      CONCLUSIONS: Our study suggests a beneficial effect of the oral dual ET receptor 
      antagonist bosentan in patients with inoperable CTEPH, urging the need for a 
      randomized, placebo-controlled trial.
FAU - Bonderman, Diana
AU  - Bonderman D
AD  - Department of Cardiology, Medical University of Vienna, Wahringer Gurtel 18-20, 
      1090 Vienna, Austria.
FAU - Nowotny, Regina
AU  - Nowotny R
FAU - Skoro-Sajer, Nika
AU  - Skoro-Sajer N
FAU - Jakowitsch, Johannes
AU  - Jakowitsch J
FAU - Adlbrecht, Christopher
AU  - Adlbrecht C
FAU - Klepetko, Walter
AU  - Klepetko W
FAU - Lang, Irene M
AU  - Lang IM
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Chest
JT  - Chest
JID - 0231335
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Endothelin Receptor Antagonists)
RN  - 0 (Sulfonamides)
RN  - EC 2.6.1.1 (Aspartate Aminotransferases)
RN  - EC 2.6.1.2 (Alanine Transaminase)
RN  - Q326023R30 (Bosentan)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Alanine Transaminase/blood
MH  - Antihypertensive Agents/*therapeutic use
MH  - Aspartate Aminotransferases/blood
MH  - Bosentan
MH  - Endothelin Receptor Antagonists
MH  - Exercise Test
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Hypertension, Pulmonary/*drug therapy
MH  - Liver Function Tests
MH  - Male
MH  - Middle Aged
MH  - Sulfonamides/*therapeutic use
MH  - Thromboembolism/*drug therapy
MH  - Walking
EDAT- 2005/10/21 09:00
MHDA- 2005/12/13 09:00
CRDT- 2005/10/21 09:00
PHST- 2005/10/21 09:00 [pubmed]
PHST- 2005/12/13 09:00 [medline]
PHST- 2005/10/21 09:00 [entrez]
AID - S0012-3692(15)52678-0 [pii]
AID - 10.1378/chest.128.4.2599 [doi]
PST - ppublish
SO  - Chest. 2005 Oct;128(4):2599-603. doi: 10.1378/chest.128.4.2599.